Tempus AI, Inc.
TEM
Clasificación en acciones
#1868
Tempus AI, Inc. operates as a healthcare technology company in the United... Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Precio por acción
$64.74
Última sincronización: 2026-10-19
Capitalización bursátil
$11.35B
Cambio (1 día)
0.03%
Cambio (1 año)
-29.97%
País
US
Comercio Tempus AI, Inc. (TEM)
Categoría
Healthcare
Ratio P/E de Tempus AI, Inc. (TEM)
Ratio P/E al October 2026 TTM: -47.78
Según los últimos informes financieros y el precio de las acciones de Tempus AI, Inc., el P/E actual (TTM) de la empresa es -47.78. Al final de 2023, la empresa tenía un P/E de -30.05.
Historial del ratio P/E de Tempus AI, Inc. desde 2019 hasta 2026
Relación P/E al final de cada año
| Año | Ratio P/E | Cambiar |
|---|---|---|
| 2026 (TTM) | -47.78 | 516.47% |
| 2024 | -7.75 | -74.20% |
| 2023 | -30.05 | 27.39% |
| 2022 | -23.59 | -10.57% |
| 2021 | -26.38 | -19.04% |
| 2020 | -32.58 | -42.10% |
| 2019 | -56.27 | 0.00% |
Relación P/E para empresas similares o competidores
| Empresa | P/E Ratio | Diferencia del P/E Ratio | País |
|---|---|---|---|
| 19.68 | -141.18% |
US
|
|
| 64.40 | -234.80% |
AU
|
|
| 44.30 | -192.73% |
US
|
|
| -123.90 | 159.33% |
US
|
|
| - | - |
US
|
¿Cómo leer un P/E ratio?
El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.
Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.
Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.